AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

9.720

-0.340-3.38%

Volume:938.12K

Turnover:9.19M

Market Cap:3.29B

PE:161.78

High:10.080

Open:10.080

Low:9.665

Close:10.060

52wk High:31.970

52wk Low:9.590

Shares:338.72M

Float Shares:275.41M

Volume Ratio:0.64

T/O Rate:0.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.060

EPS(LYR):0.204

ROE:3.14%

ROA:2.08%

PB:5.54

PE(LYR):47.71

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Says JPMorgan Chase Lifts Stake

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

BUZZ-Australia's Telix Pharma falls to over 2-year low as chair resigns

Telix Full Year Results 2025 Investor Webcast Notification

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regulatory Setbacks And Rising Investor Caution

Simply Wall St.

ASX Biggest Losers

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals slides to two-year low as chair steps down

BRIEF-Telix Pharmaceuticals Says Mark Nelson Appointed Interim Chair

Telix Pharmaceuticals Ltd-Chair Resignation, DR Mark Nelson Appointed Interim Chair

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Tiffany Olson Resigns as Non-Executive Director and Board Chair

THOMSON REUTERS

Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?

Simply Wall St.

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones

Simply Wall St.

ASX Stocks That May Be Trading Below Their Estimated Value In January 2026

Simply Wall St.

How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Simply Wall St.

ASX Growth Companies With High Insider Ownership In January 2026

Simply Wall St.

Stock Track | Telix Pharmaceuticals Plummets 5.05% as Q4 Results Fail to Excite Investors

BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 results

Telix Achieves FY 2025 Guidance With US$804M (a$1.2B) Revenue, Accelerates Growth With Gozellix Launch

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Achieves FY 2025 Unaudited Revenue of US$804 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":9.72,"timestamp":1770776435016,"preClose":10.06,"halted":0,"volume":938122,"delay":0,"changeRate":-0.03379721669980118,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.06008172467239679,"marketStatus":"Trading","change":-0.34,"latestTime":"02-11 13:20:49 AEDT","open":10.08,"high":10.08,"low":9.665,"amount":9187873,"amplitude":0.041252,"askPrice":9.73,"askSize":3577,"bidPrice":9.72,"bidSize":17674,"shortable":3,"etf":0,"ttmEps":0.06008172467239679,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770786000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":10.06,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.6398,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.08%","roe":"3.14%","lyrEps":0.203748,"volumeRatio":0.6398,"shares":338721355,"dividePrice":0,"high":10.08,"amplitude":0.041252,"preClose":10.06,"low":9.665,"week52Low":9.59,"pbRate":"5.54","psRate":"3.52","week52High":31.97,"institutionHeld":0,"latestPrice":9.72,"committee":0.663357,"eps":0.06008172467239679,"divideRate":0,"volume":938122,"delay":0,"ttmEps":0.06008172467239679,"open":10.08,"prevYearClose":11.2,"prevWeekClose":9.85,"prevMonthClose":10.55,"prevQuarterClose":11.2,"fiveDayClose":10.12,"twentyDayClose":11,"sixtyDayClose":14.98,"earningDate":1771430400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610450724","title":"Telix Pharmaceuticals Says JPMorgan Chase Lifts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2610450724","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610450724?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:30","pubTimestamp":1770607852,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 6.62% from 5.54%, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates now own 22.4 million shares in the company, the filing said.The company's shares fell around 1% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BYXW3230.USD","IE00BJTD4N35.SGD","LU0323591593.USD","LU1670627923.USD","LU0496365809.HKD","LU1974910355.USD","LU0345769631.USD","LU0320765489.SGD","LU0170899867.USD","IE00BKVL7J92.USD","LU0070302665.USD","IE00BDCRKT87.USD","BK4585","LU0683600562.USD","LU0820561909.HKD","LU0943347566.SGD","LU1894683348.USD","LU2237443622.USD","IE00BJTD4V19.USD","LU0208291251.USD","LU0211326755.USD","LU1670628061.USD","LU1244550577.SGD","LU2242649171.HKD","LU0820561818.USD","LU2552382058.USD","LU2237443382.USD","LU0971096721.USD","IE00B3S45H60.SGD","LU1032466523.USD","LU0976567544.SGD","LU2462157665.USD","IE00B775SV38.USD","LU0211328371.USD","LU0345770308.USD","TLX.AU","IE00BWXC8680.SGD","LU1064131342.USD","LU0417517546.SGD","IE00BDRTCR15.USD","BK4139","LU0310799852.SGD","TLX","BK4504","IE00B1BXHZ80.USD","LU0106831901.USD","LU0882574139.USD","LU1116320901.HKD","LU2054465674.USD","LU2237443465.HKD"],"gpt_icon":0},{"id":"2610071765","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2610071765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610071765?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:27","pubTimestamp":1770607658,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.Challenger : -3%, AU$8.61GQG Partners : -2%, AU$1.667Brambles : -1%, AU$23.2Spark New Zealand : -1%, AU$1.88SEEK : -0.6%, AU$18.21AUB Group : -0.7%, AU$27.7Contact Energy  : -0.5%, AU$8.23Lendlease Group : -0.4%, AU$4.55Telix Pharmaceuticals : -0.6%, AU$9.8The Lottery : -0.4%, AU$5.22","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7078","BK7002","BK7001","BK7006","GQG.AU","TLX.AU","LLC.AU","BK7121","BXB.AU","BK7062","BK7101","BK7042","BK7064","BK7112","SPK.AU","TLC.AU","BK7063","CGF.AU","AUB.AU","AMC.AU","SEK.AU","BK7067","JBH.AU","CEN.AU"],"gpt_icon":0},{"id":"2609530079","title":"BUZZ-Australia's Telix Pharma falls to over 2-year low as chair resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530079","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609530079?lang=en_us&edition=fundamental","pubTime":"2026-02-06 11:53","pubTimestamp":1770350004,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharma falls to over 2-year low as chair resigns** Shares of Australia's Telix Pharmaceuticals TLX.AX down 7.3% so far this week, set for their steepest weekly drop since the we","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z208X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2608383457","title":"Telix Full Year Results 2025 Investor Webcast Notification","url":"https://stock-news.laohu8.com/highlight/detail?id=2608383457","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608383457?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:38","pubTimestamp":1770154680,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT .An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday 20 February 2026 .Annie Kasparian Telix Pharmaceuticals Limited Director Investor Relations and Corporate Communications Email: [emailprotected]. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited  in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements , wheth","market":"sh","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-full-year-results-2025-investor-webcast-notification-302678211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK7039","BK4139","BK4526","TLX","BK7067","BK4141","ASX","TLX.AU","ASX.AU","SEC.AU"],"gpt_icon":0},{"id":"2608825088","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Regulatory Setbacks And Rising Investor Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2608825088","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608825088?lang=en_us&edition=fundamental","pubTime":"2026-02-03 12:51","pubTimestamp":1770094266,"startTime":"0","endTime":"0","summary":"Regulatory setbacks put Telix Pharmaceuticals (ASX:TLX) under closer investor scrutiny\nTelix Pharmaceuticals (ASX:TLX) is back in focus after three FDA rejections and an ongoing SEC investigation. These events have coincided with a sharp share price pullback and heightened regulatory risk.\nSee our latest analysis for Telix Pharmaceuticals.\nThe regulatory setbacks have coincided with a steep reset in sentiment, with a 90 day share price return of a 33.46% decline and a 1 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-regul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","TLX","BK4139","BK7067"],"gpt_icon":0},{"id":"2608438628","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2608438628","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608438628?lang=en_us&edition=fundamental","pubTime":"2026-02-03 11:20","pubTimestamp":1770088812,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Tuesday.Contact Energy : -5%, AU$8.06Ventia Services Group : -4%, AU$5.55Telix Pharmaceuticals : -3%, AU$10.14Ebos Group : -2%, AU$21.9Mineral Resources : -2%, AU$55.24Meridian Energy : -2%, AU$4.83ARB : -2%, AU$25.81Abacus Storage King : -2%, AU$1.53Virgin Australia Holdings : -2%, AU$3.1Summerset Group Holdings  : -1%, AU$10","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7103","BK7067","VGN.AU","BK7504","BK7151","BK7060","BK7055","BK7006","TLX.AU","VNT.AU","MEZ.AU","ASK.AU","CEN.AU","ARB.AU","BK7113","BK7051","MIN.AU","SNZ.AU","BK7030","BK7507","BK7095","EBO.AU"],"gpt_icon":0},{"id":"2608817704","title":"BUZZ-Australia's Telix Pharmaceuticals slides to two-year low as chair steps down","url":"https://stock-news.laohu8.com/highlight/detail?id=2608817704","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608817704?lang=en_us&edition=fundamental","pubTime":"2026-02-03 10:18","pubTimestamp":1770085121,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals slides to two-year low as chair steps down** Shares of Telix Pharmaceuticals TLX.AX fall as much as 3.6% to A$10.1, their lowest level since January 11, 2024** Chair Tiffany Olson steps down, while Mark Nelson will take over as interim** Shares mark their biggest intraday pct drop since January 30** TLX stock down 5.8% in January  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL4N3YZ05I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2608381390","title":"BRIEF-Telix Pharmaceuticals Says Mark Nelson Appointed Interim Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2608381390","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608381390?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:07","pubTimestamp":1770070070,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says Mark Nelson Appointed Interim ChairFeb 3  - Telix Pharmaceuticals TLX.AX:CHAIR RESIGNATION, DR MARK NELSON APPOINTED INTERIM CHAIRTIFFANY OLSON RESIGNS AS NON-EXECUTIVE DIRECTOR AND BOARD CHAIRFurther company coverage: TLX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUE6PZCZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2608813923","title":"Telix Pharmaceuticals Ltd-Chair Resignation, DR Mark Nelson Appointed Interim Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2608813923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608813923?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:07","pubTimestamp":1770070026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUE6PZCZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2608139288","title":"Telix Pharmaceuticals Ltd - Tiffany Olson Resigns as Non-Executive Director and Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2608139288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608139288?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:07","pubTimestamp":1770070026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUE6PZCZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2608131070","title":"Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608131070","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608131070?lang=en_us&edition=fundamental","pubTime":"2026-01-31 23:41","pubTimestamp":1769874099,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals reported that China’s NMPA has accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px (Illuccix®), supported by a pivotal Phase 3 study in Chinese patients with biochemical recurrence.\nIn parallel, the first patient has now been dosed in a Phase 3 registration study in Japan, highlighting Telix’s push to expand TLX591-Px across major Asian nuclear medicine markets in prostate cancer care.\nWe’ll next examine how this progress toward broader...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-asian-tlx591-px-expansion-progress-change-the-bull-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PRGS","BK7067","BK4097","TLX.AU","BK4139","LU2065732104.USD","TLX"],"gpt_icon":0},{"id":"2607722363","title":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722363","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607722363?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:43","pubTimestamp":1769643780,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px  for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital  in Kamakura, Japan.Illuccix Japan[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of 68Ga-PSMA-11 PET/CT[2] in Japanese patients with biochemically recurrent  prostate cancer following prior radical prostatectomy. The study will enroll up to 105 Japanese men at 11 sites and data are intended to support a future marketing authorization application for TLX591-Px in Japan.The primary objective of the study is to compare the sensitivity of 68Ga-PSMA-11 PET/CT to conventional imaging  for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and to","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/first-patient-dosed-in-pivotal-phase-3-study-of-tlx591-px-illuccix-for-prostate-cancer-imaging-in-japanese-patients-302673282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","TLX.AU","BK4543","ASX.AU","BK4141","ASX","BK7039","BK4139","BK4526","SEC.AU","BCR","BK7067"],"gpt_icon":0},{"id":"2606614203","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Key China And US Prostate Cancer Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2606614203","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606614203?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:33","pubTimestamp":1769470391,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after Chinese regulators accepted a New Drug Application for its Illuccix prostate cancer imaging agent, and the company reported first patient dosing in a US Phase 3 diagnostic trial.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the regulatory momentum in China and the US, Telix’s share price return over the past 90 days shows a 34.31% decline, contributing to a 60.23% drop in 1-year total shareholder return. However, the 5-year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-key-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","BK7067","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2606269605","title":"ASX Stocks That May Be Trading Below Their Estimated Value In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606269605","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606269605?lang=en_us&edition=fundamental","pubTime":"2026-01-26 03:04","pubTimestamp":1769367894,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty marked by mixed unemployment figures and global economic tensions, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying stocks that could be trading below their estimated value can be particularly appealing, as they offer potential for growth when market conditions stabilize.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice1-main-header/1585186745257"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-stocks-that-may-be-trading-below-their-estimated-value-i-6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-jhx/james-hardie-industries-shares/news/asx-stocks-that-may-be-trading-below-their-estimated-value-i-6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7078","BK7133","XAO.AU","BET.AU","BK7047","SPZ.AU","ABV.AU","TLX.AU","BK7044","BK7104","JHX.AU","BK7504","BK7084","DRO.AU","XKO.AU","BK7154","BK7164","BK7016","LGI.AU","BK7095","RMS.AU","BK7060","BK7506","BK7153","BK7051","GLN.AU","BK7122","XJO.AU","360.AU","KGN.AU","BK7049","BK7115","CMW.AU","BK7067","SRV.AU"],"gpt_icon":0},{"id":"2605595236","title":"How China NMPA NDA Acceptance and US BiPASS Milestone At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2605595236","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605595236?lang=en_us&edition=fundamental","pubTime":"2026-01-24 14:32","pubTimestamp":1769236341,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently reported that China’s NMPA accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px, while the first U.S. patient was dosed in the BiPASS Phase 3 trial assessing Illuccix and Gozellix in pre-biopsy diagnosis.\nEarly data showing high positive predictive value in Chinese patients and a trial aimed at reducing unnecessary biopsies highlight how Telix’s PSMA-PET portfolio could influence prostate cancer care pathways across major...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-china-nmpa-nda-acceptance-and-us-bipass-milestone-at-tel","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","BK4139","TLX"],"gpt_icon":0},{"id":"2605414594","title":"ASX Growth Companies With High Insider Ownership In January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414594","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605414594?lang=en_us&edition=fundamental","pubTime":"2026-01-23 03:09","pubTimestamp":1769108984,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a boost from Wall Street's positive momentum and ongoing discussions around international trade, investors are keenly observing the implications of these global developments on local indices. In this context, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business in navigating such complex economic landscapes.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice2-main-header/1585186554136"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-pol/polymetals-resources-shares/news/asx-growth-companies-with-high-insider-ownership-in-january-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-pol/polymetals-resources-shares/news/asx-growth-companies-with-high-insider-ownership-in-january-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TTT.AU","BK7036","EIQ.AU","EMR.AU","LM8.AU","TLX","BK7016","BK7093","3DP.AU","BK4139","PWH.AU","TLX.AU","BK7067","SEA.AU","BK7104","WZR.AU","BK7116","AV1.AU","BK7095","POL.AU","BK7506","BK7051","BK7117","NWF.AU"],"gpt_icon":0},{"id":"1137397928","title":"Stock Track | Telix Pharmaceuticals Plummets 5.05% as Q4 Results Fail to Excite Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1137397928","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137397928?lang=en_us&edition=fundamental","pubTime":"2026-01-21 07:58","pubTimestamp":1768953499,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (TLX.AU) saw its shares plummet 5.05% during intraday trading on Wednesday, marking one of its sharpest declines in recent weeks.The drop followed the company's Q4 2025...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"gpt_icon":0},{"id":"2605140624","title":"BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2605140624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605140624?lang=en_us&edition=fundamental","pubTime":"2026-01-21 07:56","pubTimestamp":1768953364,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals down as Citi sees no surprise in Q4 resultsUpdates** Shares of Australia's Telix Pharmaceuticals TLX.AX fall as much as 5.1% to A$10.9, their lowest level since Jan. 8** Stock logs its biggest intraday pct loss since Dec. 17** Citi says TLX's fourth-quarter results did not provide any major numerical surprises** TLX, after market hours on Tuesday, reported revenue of $208 million, up 46% year-on-year** Citi says revenue in line with Visible Alpha and its estimates** Brokerage says investors would likely shrug off results and instead focus on short-term milestone events for co's products** Earlier this week, TLX said China's NMPA accepted its New Drug Application for prostate imaging cancer product** Citi analysts, however, do not see the news as a major driver for stock** Citi keeps \"buy/high risk\" rating for TLX, target price of A$34 apiece** All 13 analysts covering the stock rate it \"buy\" or higher; their median PT is A$24.75 – LSEG data** Stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4N3YL28S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2764262908.HKD","SG9999014906.USD","LU0971096721.USD","LU1989764664.SGD","BK7067","SG9999018865.SGD","LU2720916845.USD","TLX.AU","LU0345774391.USD","BK4585","BK4597","LU0097036916.USD","BK4588","LU1804176565.USD","LU2095319765.USD","LU1496350502.SGD","SG9999014880.SGD","SG9999018857.SGD","LU1989763005.USD","LU2210149790.SGD","SPGI","LU2264538146.SGD","LU0154236417.USD","GB00BDT5M118.USD","LU0342679015.USD","LU0289960550.SGD","SG9999014914.USD","LU1064131342.USD","IE00B19Z9505.USD","LU2210150020.SGD","SGXZ31699556.SGD","BK4112","LU1633808545.USD","SG9999014898.SGD","BK4548","LU2028103732.USD","SG9999017495.SGD","LU2089284900.SGD","BK4581","LU0158827781.USD","LU0985320562.USD","LU2271345857.HKD","BK4534","LU2089283258.USD","LU0868494617.USD","LU2265009873.SGD","LU1989764748.USD","LU1989772923.USD","LU0345774631.USD","LU0158827948.USD"],"gpt_icon":0},{"id":"2604190368","title":"Telix Achieves FY 2025 Guidance With US$804M (a$1.2B) Revenue, Accelerates Growth With Gozellix Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190368?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA4P619M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2604190333","title":"Telix Pharmaceuticals Ltd - Achieves FY 2025 Unaudited  Revenue of US$804 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190333?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUA4P619M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":148,"code":"91000000","status":"200"}]}}